Morgan Harloff

Morgan Harloff

Auto-generated profile, based on publicly available information

Morgan Harloff

Division of Cardiac Surgery, Department of Surgery, Boston Medical Center, Boston University Chobanian & Avedisian School of Medicine, Boston, MA 02118, USA

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2022 in Seminars in Thoracic and Cardiovascular Surgery
Verified
Journal Article
Closed access
PDF file
FYFarhang Yazdchi
Farhang Yazdchi
SHSameer A Hirji
Sameer A Hirji
MHMorgan Harloff
Morgan Harloff
SMSiobhan McGurk
Siobhan McGurk
KMKaren Morth
Karen Morth
SASary Aranki
Sary Aranki

28 March 2022 in The American Journal of Cardiology
Verified
Journal Article
Closed access
PNPaige Newell
Paige Newell
SHSameer Hirji
Sameer Hirji
AMAlexandra Malarczyk
Alexandra Malarczyk
FYFarhang Yazdchi
Farhang Yazdchi
EPEdward Percy
Edward Percy
TKTsuyoshi Kaneko
Tsuyoshi Kaneko

9 April 2026 in The Heart Surgery Forum
Verified
Journal Article
Open access
PDF file
SSSophia M. Smith
Sophia M. Smith
MHMorgan Harloff
Morgan Harloff
AKAlexandros N. Karavas
Alexandros N. Karavas
Background: Lipomatous hypertrophy of the interatrial septum is rare, and extension to surrounding structures is extremely uncommon, yet may result in obstructive symptoms requiring surgical resection. Case: This case report describes a 56-year-old male who had been undergoing an outpatient workup for lightheadedness, palpitations, and chest pain. Computed tomography revealed a large mass extending from the superior vena cava to the atrial septum, resulting in compression of the superior vena cava. Magnetic resonance imaging suggested lipomatous characteristics. Subsequently, the patient was referred for cardiac surgery and underwent an uncomplicated resection of the mass and reconstruction of the superior vena cava, with ensuing resolution of the symptoms. Conclusion: Lipomatous hypertrophy of the interatrial septum can rarely expand into the superior vena cava, causing obstructive symptoms. Symptomatic relief may be achieved via resection of the entire mass, which can be performed without violating the atrial septum and atrial wall.

1 March 2020 in JACC
Verified
Journal Article
Closed access
SHSameer A Hirji
Sameer A Hirji
TKTsuyoshi Kaneko
Tsuyoshi Kaneko
SMSiobhan McGurk
Siobhan McGurk
OCOlena Cherkasky
Olena Cherkasky
HAHasan Ahmed
Hasan Ahmed
GTGilbert Tang
Gilbert Tang

24 July 2023 in JTCVS Open
Verified
Journal Article
Open access
PNPaige Newell
Paige Newell
HJHoda Javadikasgari
Hoda Javadikasgari
MRMehida Rojas-Alexandre
Mehida Rojas-Alexandre
SHSameer A Hirji
Sameer A Hirji
MHMorgan Harloff
Morgan Harloff
TKTsuyoshi Kaneko
Tsuyoshi Kaneko
With expanding eligibility criteria, transcatheter aortic valve replacement is being performed on patients with longer life expectancy, and subsequent procedures after index transcatheter aortic valve replacement are inevitable. This study examines the incidence and outcomes of patients undergoing subsequent procedural readmissions after transcatheter aortic valve replacement. All patients who underwent index transcatheter aortic valve replacement and were discharged alive from January 2012 to December 2019 at a single institution were evaluated. Study end points were mortality and readmission for procedure with more than 1-day hospital stay. Effect on survival was evaluated by treating procedural readmission as a time-dependent variable by Cox proportional hazard model and competing risk analysis. A total of 1092 patients met inclusion criteria with a median follow-up time of 34 months. A total of 218 patients (20.0%) had 244 subsequent procedural readmissions. During the 244 procedural readmissions, there were 260 procedures; 96 (36.9%) were cardiac (most commonly pacemaker implantation, percutaneous coronary interventions, and surgical aortic valve replacements), and 164 (63.1%) were noncardiac (most commonly orthopedic and gastrointestinal procedures). The overall procedural readmission rates were 32%, 39%, and 42%, and all-cause mortality was 27%, 44%, and 54% at 20, 40, and 60 months, respectively. Procedural readmissions were not associated with a survival penalty in any surgical risk group or on Cox regression (hazard ratio, 1.25; 0.91-1.64, P = .17). After transcatheter aortic valve replacement, procedural interventions are seen frequently, with most procedures occurring within the first year after transcatheter aortic valve replacement. However, subsequent procedural readmissions do not appear to have a survival penalty for patients after transcatheter aortic valve replacement. After transcatheter aortic valve replacement with resolution of aortic stenosis, subsequent procedures can and should be pursued if they are needed.

1 January 2025 in Journal of Cardiac Surgery
Verified
Journal Article
Open access
TVThais Faggion Vinholo
Thais Faggion Vinholo
Andreas HabertheuerAndreas Habertheuer
Andreas Habertheuer
MHMorgan Harloff
Morgan Harloff
SHSameer A Hirji
Sameer A Hirji
FYFarhang Yazdchi
Farhang Yazdchi
SASary Aranki
Sary Aranki
Background: Severe calcific disease of the ascending aorta may prohibit cross‐clamping during coronary artery bypass grafting (CABG) due to unacceptable morbidity and mortality associated with atheroembolic complications. Clampless hypothermic noncardioplegic low flow fibrillation (HLFF) may minimize neurologic complications while allowing for complete revascularization. Methods: From 2002 to 2019, 142 patients with unclampable aorta (UCA) underwent isolated CABG using clampless HLFF. Short‐term and long‐term outcomes were compared with an isolated conventional on‐pump CABG cohort ( n = 268) risk‐matched (RM) for type of CABG, STS score, age, and sex. Results: UCA and RM cohort patients were comparable in terms of age (73.7 ± 7.8 vs. 72.7 ± 8.7, p = 0.281), sex (34.4% vs. 32.5% female, p = 1.000), STS score (4.01 ± 3.43 vs. 3.80 ± 3.33, p = 0.539), and number of diseased vessels ( p = 0.323). 90% of patients underwent central cannulation; UCA group patients received a comparable number of arterial ( p = 0.432) or venous grafts ( p = 0.493). Incidence of stroke was 6.3% in the UCA cohort and 2.6% in the RM cohort ( p = 0.059). Need for reoperation, postoperative transfusions, incidence of atrial fibrillation, and renal impairment was similar (all p > 0.050). UCA patients spent a longer time on the ventilator, in the ICU, and in the hospital (all p = 0.001). Operative mortality was not different between UCA and RM groups (3.5% vs. 4.5%, p = 0.797) as was all‐cause mortality over long‐term follow‐up ( p = 0.093). Conclusions: While a higher incidence of stroke was observed, without reaching statistical significance, hypothermic fibrillatory arrest remains a valuable and safe tool for coronary revascularization in UCA patients, offering comparable short‐term and long‐term survival outcomes allowing for complete revascularization.